Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2021
Reporting Period: Event date August 19, 2021; Expected closing August 23, 2021.
Context: The Company entered into a securities purchase agreement for a Registered Direct Offering and a concurrent private placement to raise capital.
Key Financial Metrics and Transaction Details
| Item | Details |
|---|---|
| Securities Issued (Registered Direct) | 8,430,000 shares of Common Stock ($5.00/share) and Pre-Funded Warrants for 5,570,000 shares ($4.999/warrant). |
| Securities Issued (Private Placement) | Series A Warrants to purchase up to 7,000,000 shares of Common Stock ($5.00 exercise price). |
| Expected Gross Proceeds | Approximately $70 million (before fees and expenses). |
| Placement Agent Fees | 7.5% of gross proceeds plus a 1% management fee. |
| Placement Agent Warrants | 1,050,000 warrants issued to H.C. Wainwright & Co., LLC at $6.25 exercise price. |
Note: This filing does not provide historical revenue, profit, cash flow, or debt metrics. It focuses solely on the capital raise transaction.
Material Changes and Transaction Structure
- Capital Raise: The Company is executing a significant equity financing event to raise approximately $70 million.
- Instrument Mix: The offering utilizes a combination of common stock, pre-funded warrants (exercisable immediately at $0.001), and standard warrants (Series A, exercisable immediately at $5.00, expiring in 5 years).
- Agent Compensation: H.C. Wainwright & Co., LLC serves as the exclusive placement agent, receiving cash fees totaling 8.5% of gross proceeds and additional warrants representing 7.5% of the registered securities sold.
- Regulatory Status: The Registered Direct Offering is pursuant to an effective Form S-3 shelf registration. The Series A and Placement Agent Warrants are unregistered, relying on Section 4(a)(2) and Regulation D exemptions.
Outlook, Risks, and Management Commentary
- Closing Conditions: The transaction is expected to close on August 23, 2021, subject to customary closing conditions.
- Forward-Looking Statements: The filing includes standard disclaimers that actual outcomes may differ materially from expectations due to risks discussed in the Company's Form 10-K and Prospectus Supplement.
- Legal Opinions: Legal opinions regarding the validity of the securities have been obtained from Ballard Spahr LLP and Troutman Pepper Hamilton Sanders LLP.
- Indemnification: The Company agreed to indemnify Purchasers against certain liabilities under the Securities Act and breaches of representations.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $70 million gross proceeds receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Assess the dilution impact of the 8,430,000 shares, 5,570,000 pre-funded warrants, and 7,000,000 Series A warrants on existing shareholders.
- Confirm the use of proceeds as detailed in the accompanying press release (Exhibit 99.1).
- Monitor the Company's cash position post-closing to evaluate liquidity improvements.